A049180 Stock Overview
A biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cellumed Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,270.00 |
| 52 Week High | ₩4,415.00 |
| 52 Week Low | ₩1,351.00 |
| Beta | 0.87 |
| 11 Month Change | -18.35% |
| 3 Month Change | 36.09% |
| 1 Year Change | -14.18% |
| 33 Year Change | -62.10% |
| 5 Year Change | -62.04% |
| Change since IPO | -78.48% |
Recent News & Updates
Benign Growth For Cellumed Co.,Ltd. (KOSDAQ:049180) Underpins Stock's 35% Plummet
Nov 01
Cellumed Co.,Ltd.'s (KOSDAQ:049180) Low P/S No Reason For Excitement
Aug 27Shareholder Returns
| A049180 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -0.9% | 8.1% | 2.9% |
| 1Y | -14.2% | 11.5% | -2.8% |
Return vs Industry: A049180 underperformed the KR Medical Equipment industry which returned 11.5% over the past year.
Return vs Market: A049180 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A049180 volatility | |
|---|---|
| A049180 Average Weekly Movement | 23.3% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A049180's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A049180's weekly volatility has increased from 14% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 99 | In-soo Yoo | www.cellumed.co.kr |
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones.
Cellumed Co.,Ltd. Fundamentals Summary
| A049180 fundamental statistics | |
|---|---|
| Market cap | ₩116.92b |
| Earnings (TTM) | -₩30.24b |
| Revenue (TTM) | ₩111.87b |
1.0x
P/S Ratio-3.9x
P/E RatioIs A049180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A049180 income statement (TTM) | |
|---|---|
| Revenue | ₩111.87b |
| Cost of Revenue | ₩100.27b |
| Gross Profit | ₩11.60b |
| Other Expenses | ₩41.84b |
| Earnings | -₩30.24b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -587.07 |
| Gross Margin | 10.37% |
| Net Profit Margin | -27.03% |
| Debt/Equity Ratio | 27.9% |
How did A049180 perform over the long term?
See historical performance and comparison